Trial Profile

A study to determine risk of test-positive SARS-CoV-2 infection after three doses of BNT162b2 or mRNA-1273 in Inflammatory Rheumatic Diseases (IRD) patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jul 2023 New trial record
03 Jun 2023 According to Results presented at the 24th Annual Congress of the European League Against Rheumatism, following two doses of BNT162b2 or mRNA-1273 participants were invited to participate in the next phase of the study.
03 Jun 2023 Results (n=145) of an analysis assessing risk of test-positive SARS-CoV-2 infection after three doses presented at the 24th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com